S&P 500
7,509.40
+0.25%
Dow Jones
52,468.10
+0.21%
Nasdaq 100
29,944.10
+0.26%
Russell 2000
3,017.86
+0.15%
FTSE 100
10,505.80
+0.17%
Nikkei 225
69,572.30
-0.08%
Haemonetics

Haemonetics (HAE) Q4 2026 Earnings

Reported May 7, 2026 at 6:02 AM ET · SEC Source

Q4 26 EPS

$1.29

BEAT +1.38%

Est. $1.27

Q4 26 Revenue

$346.4M

BEAT +2.82%

Est. $336.9M

vs S&P Since Q4 26

+31.2%

BEATING MARKET

HAE +33.2% vs S&P +1.9%

Full Year 2026 Results

FY 26 EPS

$4.96

FY 26 Revenue

$1.33B

Market Reaction

Did HAE Beat Earnings? Q4 2026 Results

Haemonetics closed out fiscal 2026 on a note of underlying strength overshadowed by a significant accounting charge, as the blood management company posted Q4 adjusted earnings of $1.29 per diluted share, edging past the $1.27 consensus estimate by 1… Read more Haemonetics closed out fiscal 2026 on a note of underlying strength overshadowed by a significant accounting charge, as the blood management company posted Q4 adjusted earnings of $1.29 per diluted share, edging past the $1.27 consensus estimate by 1.38%, while revenue of $346.35 million grew 4.8% year over year and cleared analyst expectations by 2.82%. The standout driver was the Hospital segment, where Blood Management Technologies surged 22.4%, helping offset a 9.6% reported decline in Interventional Technologies. A $77.25 million impairment of intangible assets tied to the Attune Medical acquisition, however, swung GAAP results to a net loss of $20.15 million, a sharp reversal from $57.98 million in net income a year ago, which rattled investors and sent shares down roughly 9.5% in the aftermath. Organic revenue growth excluding the CSL wind-down reached 8.6%, illustrating the business's underlying momentum. Looking ahead, management guided fiscal 2027 reported revenue growth of 4% to 7%, with adjusted operating margin expansion of 50 to 100 basis points and free cash flow conversion of approximately 80%.

Key Takeaways

  • • Blood Management Technologies revenue grew 22.4% YoY in Q4, driving Hospital segment outperformance
  • • Plasma organic ex-CSL growth of 12.7% reflects underlying strength once CSL transition impact is excluded
  • • Adjusted gross margin declined 50 basis points due to less favorable mix and tariff impacts, partially offset by higher volume and pricing
  • • Attune Medical intangible asset impairment of $77.2 million and $7.4 million pre-acquisition inventory provision impacted GAAP results

HAE Forward Guidance & Outlook

For fiscal 2027, Haemonetics guided reported revenue growth of 4-7% (including approximately 2% headwind from a 53rd week comparison and 0-1% currency impact), organic revenue growth of 3-6% (including mid-single-digit growth in each of Plasma and Hospital and a mid-single-digit decline in Blood Center), adjusted operating margin expansion of 50-100 basis points year-over-year, adjusted earnings per diluted share growth comparable to revenue growth, and free cash flow conversion of approximately 80%.

24/7 Wall St

HAE YoY Financials

Q4 2026 vs Q4 2025, source: SEC Filings

24/7 Wall St

HAE Revenue by Segment

With YoY comparisons, source: SEC Filings

Q1 26 Q4 26

“Strong fourth quarter performance was largely driven by our core platforms, with outperformance in Plasma and Blood Management Technologies, and sequential improvement in Interventional Technologies. We successfully completed our four-year long-range plan, having built a more diversified, sustainable, and durable business and delivering impressive results against ambitious multi-year goals. With a strengthened competitive position and focus on disciplined execution, we have momentum for fiscal 2027 and beyond.”

— Chris Simon, Q4 2026 Earnings Press Release

Back to HAE Stock Page